AOD-9604 is a fragment of human growth hormone, marketed for years as a “fat-burning peptide” that melts fat without growth hormone’s downsides. It has a tidy theory and — unusually for this corner of the market — actual human trials.
The problem is what those trials found: in the key obesity study, AOD-9604 did not produce significantly more fat loss than placebo. That result is why its development stalled. If you are weighing AOD-9604 for fat loss, this is the honest verdict the sales pages skip.
What AOD-9604 is
AOD-9604 is a small peptide corresponding to the C-terminal region (amino acids 176-191) of human growth hormone — the part of the molecule thought to be responsible for GH’s fat-metabolism effects. The idea was to isolate the fat-burning signal while leaving out the growth-promoting and blood-sugar effects of full growth hormone. For the overview, see what is AOD-9604.
AOD-9604 is the rare research peptide that actually got proper human trials — and the rare one whose trials politely said ‘no better than placebo.’Why the evidence matters more than the theory
The theory
On paper it is elegant. Growth hormone promotes lipolysis — the breakdown of stored fat — and AOD-9604 was engineered to reproduce that specific effect. In early laboratory and animal work it did appear to stimulate fat breakdown and inhibit fat formation, without raising IGF-1 or affecting blood sugar the way full GH does. That clean mechanism is what fuelled the “fat loss without the downsides” marketing.
What the trials showed
Here is where theory met reality. AOD-9604 was developed as an obesity drug and taken into human clinical trials by its developer. The animal promise did not carry over: in the pivotal human obesity trial, AOD-9604 failed to produce statistically significant weight or fat loss compared with placebo. Without an efficacy signal, its development as an anti-obesity drug was discontinued. It later found a second life mainly as a research peptide and in some cosmetic and veterinary contexts — not as a proven human fat-loss treatment.
Does it actually work?
On the best available human evidence: not demonstrably, for fat loss. The compound appears safe and well tolerated in studies, but “safe” is not “effective.” The pivotal trial that would have proven a fat-loss benefit did not, and nothing since has established one. Compared with the GLP-1 drugs — which produce 15-28% weight loss in trials — AOD-9604 is simply not in the same conversation on evidence. If fat loss is the goal, see weight-loss injections in Canada and the GLP-1 drugs guide for what the data actually supports.
AOD-9604 is not an approved weight-loss or fat-loss drug, and its pivotal human obesity trial did not beat placebo. TrueLabs sells it for in vitro and laboratory research only. This article is research background, not medical advice or dosing guidance.
For researchers
TrueLabs supplies AOD-9604 from $23, alongside the GH-axis compounds Tesamorelin from $37 and Ipamorelin from $40, in CAD for in vitro and laboratory research only. Before ordering, see how to read a peptide COA and the COA library.
AOD-9604 myths
“Myth: AOD-9604 is a proven fat-burner.”
Its pivotal human obesity trial did not beat placebo. The animal promise did not translate to people.
“Myth: It works like the GLP-1 drugs.”
Not remotely. GLP-1 drugs produce large, proven weight loss; AOD-9604 has no demonstrated human fat-loss effect.
“Myth: Being a GH fragment means it builds muscle too.”
It was designed to isolate fat metabolism and does not raise IGF-1 like GH; it is not a muscle-building compound.
“Myth: Safe means effective.”
It appears well tolerated, but tolerability is not efficacy, and the efficacy was not shown.
FAQ
Tap a question to reveal the answer.
Does AOD-9604 work for fat loss?
Not on the best human evidence. In its pivotal obesity trial it did not produce significantly more fat or weight loss than placebo, which is why development as an anti-obesity drug stopped.
What is AOD-9604?
A peptide fragment of growth hormone (amino acids 176-191) designed to reproduce GH’s fat-metabolism effect without its growth or blood-sugar effects.
How was it supposed to work?
By stimulating lipolysis (fat breakdown) and inhibiting fat formation, mimicking the fat-related action of growth hormone while avoiding raising IGF-1.
Why did development stop?
The human obesity trial failed to show a significant fat-loss benefit over placebo, so there was no efficacy case to continue as a weight-loss drug.
Is AOD-9604 safe?
It appeared well tolerated in studies, but being tolerable is not the same as being effective, and it is not an approved drug.
Is AOD-9604 better than Ozempic for weight loss?
No. GLP-1 drugs have large, proven weight loss in trials; AOD-9604 has no demonstrated human fat-loss effect. They are not comparable.
Is it approved?
No. It is not an approved weight-loss drug, and injectable peptides are regulated as prescription drugs in Canada.
Is research AOD-9604 a treatment?
No. It is a raw compound for laboratory study, not an approved or proven fat-loss treatment.
Related reading
- What is AOD-9604?
- AOD-9604 side effects
- Tesamorelin and belly fat
- The complete GLP-1 drugs guide
- Best peptides for muscle growth
References
- Metabolic Pharmaceuticals / published obesity trial data on AOD-9604 (C-terminal GH fragment 176-191). J Endocrinol Metab and related.
- Health Canada. Advisory: unauthorized injectable peptide products, 2025.
This article summarizes published research for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.